Effect of Ticagrelor Compared to Clopidogrel on Short-term Outcomes of COVID-19 Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention; a Randomized Clinical Trial
Archives of Academic Emergency Medicine,
Vol. 11 No. 1 (2023),
15 November 2022
Introduction: Acute COVID-19 infection is associated with increased adverse clinical outcomes in patients with acute coronary syndromes (ACS). Given that some studies suggested improved pulmonary function with Ticagrelor, this clinical trial aimed to compare the effects of Ticagrelor versus Clopidogrel on the short-term outcomes of these patients.
Methods: In this multicenter clinical trial, 180 COVID-19 patients with ACS who underwent urgent percutaneous coronary intervention (PCI) were randomized to receive Ticagrelor (180mg loading dose followed by 90mg twice daily, n=90) or Clopidogrel (600mg loading dose with 75mg daily, n=90), and then followed for one month after their procedure. The primary composite endpoint was a combination of all-cause mortality, myocardial infarction, and early stent thrombosis within the first month after stent implantation.
Results: After thirty days of follow-up, the primary composite endpoint was non-significantly lower in the Ticagrelor compared to the Clopidogrel group (18.5% vs 23.5% respectively, p = 0.254). Based on the time-to-event analysis, the mean survival rate was 26.8 ±7.7 and 24.7 ±9.9 days, respectively, for the Ticagrelor and the Clopidogrel arms (Log-rank p = 0.275). Secondary endpoints were similar in the two trial arms, except for the mean oxygen saturation, which was higher in the Ticagrelor group (95.28 ±2.68 % vs. 94.15 ± 3.55 %, respectively; p = 0.021).
Conclusion: Among COVID-19 patients with concomitant ACS, who were treated with urgent PCI, the composite outcome of death, myocardial infarction, and early stent thrombosis was not different between Ticagrelor and Clopidogrel groups. However, administration of Ticagrelor was associated with a slight but statistically significant increase in oxygen saturation compared to Clopidogrel, but this difference wasn’t clinically important.
- Myocardial infarction
- Percutaneous coronary intervention
How to Cite
Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666-87.
Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352-71.
Bansal M. Cardiovascular disease and COVID-19. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(3):247-50.
Tomasoni D, Adamo M, Italia L, Branca L, Chizzola G, Fiorina C, et al. Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction. J Cardiovasc Med. 2020;21(11):874-81.
Wu J, Mamas MA, Mohamed MO, Kwok CS, Roebuck C, Humberstone B, et al. Place and causes of acute cardiovascular mortality during the COVID-19 pandemic. Heart. 2021;107(2):113-9.
Jain V, Gupta K, Bhatia K, Bansal A, Arora S, Khandelwal AK, et al. Management of STEMI during the COVID-19 pandemic: Lessons learned in 2020 to prepare for 2021. Trends Cardiovasc Med. 2021;31(3):135-40.
Chew NW, Sia C-H, Wee H-L, Jia-Da Benedict L, Rastogi S, Kojodjojo P, et al. Impact of the COVID-19 Pandemic on Door-to-Balloon Time for Primary Percutaneous Coronary Intervention―Results From the Singapore Western STEMI Network―. Circ J. 2021;85(2):139-49.
De Luca G, Cercek M, Jensen LO, Vavlukis M, Calmac L, Johnson T, et al. Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. Cardiovasc Diabetol. 2020;19(1):215.
Rodriguez-Leor O, Cid-Álvarez B, Ojeda S, Martín-Moreiras J, Rumoroso JR, López-Palop R, et al. Impact of the COVID-19 pandemic on interventional cardiology activity in Spain. REC Interv Cardiol. 2020;2(2):82-9.
Scholz KH, Lengenfelder B, Thilo C, Jeron A, Stefanow S, Janssens U, et al. Impact of COVID-19 outbreak on regional STEMI care in Germany. Clin Res Cardiol. 2020;109(12):1511-21.
Choudhary R, Kaushik A, Sharma JB. COVID-19 pandemic and stent thrombosis in a post percutaneous coronary intervention patient-a case report highlighting the selection of P2Y12 inhibitor. Cardiovascular Diagnosis and Therapy. 2020;10(4):898.
Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA. Thrombosis in COVID‐19. Am J Hematol. 2020;95(12):1578-89.
Miesbach W, Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020;26:1076029620938149.
Prieto-Lobato A, Ramos-Martínez R, Vallejo-Calcerrada N, Corbí-Pascual M, Córdoba-Soriano JG. A case series of stent thrombosis during the COVID-19 pandemic. Case Reports. 2020;2(9):1291-6.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57.
Sahlén A, Varenhorst C, Lagerqvist B, Renlund H, Omerovic E, Erlinge D, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J. 2016;37(44):3335-42.
Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets. 2014;25(7):517-25.
Skorupski WJ, Grygier M, Lesiak M, Kałużna-Oleksy M. Coronary stent thrombosis in COVID-19 patients: a systematic review of cases reported worldwide. Viruses. 2022;14(2):260.
Hinterseer M, Zens M, Wimmer RJ, Delladio S, Lederle S, Kupatt C, et al. Acute myocardial infarction due to coronary stent thrombosis in a symptomatic COVID-19 patient. Clin Res Cardiol. 2021;110(2):302-6.
Kunal S, Pathak V, Pathak K, Mishra M, Sharma SM, Bhandari S. Very late stent thrombosis associated with COVID-19 infection: a case report and review of the literature. Monaldi Archives for Chest Disease. 2022;92(2):1960.
Ayan M, Kovelamudi S, Al-Hawwas M, editors. Subacute stent thrombosis in a patient with COVID-19 pneumonia. Baylor University Medical Center Proceedings; 2021;34(1):175-177. Taylor & Francis.
Kermani-Alghoraishi M. A review of coronary artery thrombosis: a new challenging finding in COVID-19 patients and ST-elevation myocardial infarction. Curr Probl Cardiol. 2021;46(3):100744.
Elkholy KO, Khizar A, Khan A, Hakobyan N, Sahni S. Subacute stent thrombosis in a patient with COVID-19 despite adherence to antiplatelets. Cureus. 2021;13(2): e13194.
Antuña P, Rivero F, Del Val D, Cuesta J, Alfonso F. Late coronary stent thrombosis in a patient with coronavirus disease 2019. JAMA cardiology. 2020;5(10):1195-8.
Galeazzi GL, Loffi M, Di Tano G, Danzi GB. Severe COVID-19 pneumonia and very late stent thrombosis: a trigger or innocent bystander? Korean Circulation Journal. 2020;50(7):632.
Montaseri M, Golchin Vafa R, Attar A, Ali Hosseini S, Kojuri J. Stent thrombosis during COVID‐19 pandemic: A case series. Clinical Case Reports. 2022;10(5):e05872.
Hamadeh A, Aldujeli A, Briedis K, Tecson KM, Sanz-Sánchez J, Al-Obeidi A, et al. Characteristics and outcomes in patients presenting with COVID-19 and ST-segment elevation myocardial infarction. The American journal of cardiology. 2020;131:1-6.
Batah SS, Fabro AT. Pulmonary pathology of ARDS in COVID-19: a pathological review for clinicians. Respir Med. 2021;176:106239.
Sexton TR, Zhang G, Macaulay TE, Callahan LA, Charnigo R, Vsevolozhskaya OA, et al. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC: Basic to Translational Science. 2018;3(4):435-49.
Xie J, Covassin N, Fan Z, Singh P, Gao W, Li G, et al., editors. Association between hypoxemia and mortality in patients with COVID-19. Mayo Clin Proc; 2020:95(6): 1138-1147 Elsevier.
Solano-López J, Zamorano JL, Sanz AP, Amat-Santos I, Sarnago F, Ibañes EG, et al. Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak. Revista Española de Cardiología (English Edition). 2020;73(12):985-93.
Mohsenizadeh SA, Alidoosti M, Jalali A, Tofighi S, Salarifar M, Poorhosseini H, et al. Comparison of Angiographic and Clinical Outcomes After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction Between Patients With and Without Concomitant COVID-19 Infection. Crit Pathw Cardiol. 2022;21(3):141-6.
Namazi MH, Saemifard F, Pishgahi M. One-Month Outcomes of Cases Receiving Ticagrelor after Percutaneous Coronary Intervention; a Case Series. Arch Acad Emerg Med [Internet]. 2020Apr.4 [cited 2022Dec.15];8(1):e42.
- Abstract Viewed: 293 times
- pdf Downloaded: 696 times